Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.56 |
| ▸ | ADA | P00813 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.52 |
| ▸ | DPP4 | P27487 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.52 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.52 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.52 |
| ▸ | GAPDH | P04406 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.52 |
| ▸ | STAT6 | P42226 | 1/20 | 0.52 |
| ▸ | PI4KA | P42356 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.52 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.52 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29403419 | 1.00 | ADORA1 (0.56) | ADORA1ADAPOLBADORA3DPP4 | |
| SCHEMBL31342871 | 0.92 | ADORA1 (0.54) | ADORA1ADAPOLBADORA3DPP4 | |
| SCHEMBL29547295 | 0.91 | ADORA1 (0.64) | ADORA1ADAPOLBSMN1; SMN2ENPP1 | |
| SCHEMBL13528511 | 0.91 | ADORA1 (0.64) | ADORA1ADAPOLBSMN1; SMN2ENPP1 | |
| SCHEMBL3502762 | 0.91 | ADORA1 (0.64) | ADORA1ADAPOLBSMN1; SMN2ENPP1 | |
| Ammonia Solution, Strong SCHEMBL7745708 | 0.89 | POLB (0.57) | ADORA1POLBSMN1; SMN2ENPP1P2RY1 | |
| SCHEMBL16245411 | 0.89 | HIF1A (0.49) | ADORA1POLBP2RY1 | |
| SCHEMBL8175190 | 0.87 | POLB (0.60) | ADORA1ADAPOLBENPP1P2RY1 | |
| SCHEMBL8167619 | 0.86 | POLB (0.59) | ADORA1POLBSMN1; SMN2ENPP1P2RY1 | |
| SCHEMBL8174805 | 0.86 | POLB (0.59) | ADORA1POLBSMN1; SMN2ENPP1P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 287 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5795756-A | Method and compounds for the inhibition of adenylyl cyclase | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 1998-08-18 | — | — | US | claimed |
| US-20260132404-A1 | MODIFIED OLIGONUCLEOTIDES AND DOUBLE-STRANDED RNAS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260103715-A1 | POLYNUCLEOTIDE AGENTS TARGETING PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS INC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4714500-A2 | HEPATITIS B VIRUS (HBV) DSRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12584130-B2 | Angiotensinogen (AGT) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260048130-A1 | ALPHA-V BETA-6 (avb6) INTEGRIN LIGANDS FOR EXTRAHEPATIC DELIVERY | ALNYLAM PHARMACEUTICALS INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-20260049312-A1 | COMPLEMENT COMPONENT C3 IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS INC (US) | 2026-02-19 | — | — | US | disclosed |
| EP-3837366-B1 | HEPATITIS B VIRUS (HBV) DSRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12553053-B2 | Transmembrane serine protease 2 (TMPRSS2) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-12551569-B2 | RNAi agents for inhibiting expression of microtubule associated protein tau (MAPT), compositions thereof, and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2026-02-17 | — | — | US | disclosed |
| US-9376680-B2 | Serpinc1 iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20160115476-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-04-28 | — | — | US | disclosed |
| US-20160017330-A1 | SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2016-01-21 | — | — | US | disclosed |
| US-9133461-B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9127274-B2 | Serpinc1 iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150111841-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2015-04-23 | — | — | US | disclosed |
| US-20130317081-A1 | SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2013-11-28 | — | — | US | disclosed |
| US-20130281511-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | BANK OF AMERICA, N.A. | 2013-10-24 | — | — | US | disclosed |
| US-6132957-A | CONTACTING A 9-SUBSTITUTED ADENINE WITH A CELL EXTRACT CONTAINING ADENYLATE CYCLASE ACTIVITY, DETECTING THE AMOUNT OF INHIBITION, AND CORRELATING WITH TEST STANDARD OR CONTROL; NOVEL THERAPIES FOR CARDIOVASCULAR DISORDERS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2000-10-17 | — | — | US | disclosed |
| US-5795756-A | Method and compounds for the inhibition of adenylyl cyclase | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 1998-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049312-A1 | COMPLEMENT COMPONENT C3 IRNA COMPOSITIONS AND METHODS OF USE THEREOF | CFH, SSB, RNASEH1 | ADORA1 4004/4885ADA 2572/4885POLB 702/4885 |
| US-12553053-B2 | Transmembrane serine protease 2 (TMPRSS2) iRNA compositions and methods of use thereof | TMPRSS2, TMPRSS11D, TMPRSS4 | ADORA1 2294/4885ADA 795/4885POLB 1821/4885 |
| US-12551569-B2 | RNAi agents for inhibiting expression of microtubule associated protein tau (MAPT), compositions thereof, and methods of use | MAPT, RNMT, NSUN2 | ADORA1 1674/4885ADA 743/4885POLB 810/4885 |
| US-20260132404-A1 | MODIFIED OLIGONUCLEOTIDES AND DOUBLE-STRANDED RNAS | RNASEL, NSUN2, ADAR | ADORA1 1461/4885ADA 66/4885POLB 144/4885 |
| US-20260048130-A1 | ALPHA-V BETA-6 (avb6) INTEGRIN LIGANDS FOR EXTRAHEPATIC DELIVERY | ITGB6, ITGA6, ITGA2B | ADORA1 1046/4885ADA 3280/4885POLB 343/4885 |
| US-20260103715-A1 | POLYNUCLEOTIDE AGENTS TARGETING PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) AND METHODS OF USE THEREOF | PDCD1LG2, CD274, PDCD1 | ADORA1 1463/4885ADA 147/4885POLB 86/4885 |
| US-12584130-B2 | Angiotensinogen (AGT) iRNA compositions and methods of use thereof | AGT, AGTR2, AGTR1 | ADORA1 1114/4885ADA 726/4885POLB 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.